A novel chalcone derivative suppresses melanoma cell growth through targeting Fyn/Stat3 pathway

Ling Tang1,2,3, Jing Long2,3,4, Keke Li2,3,4

  • 1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan China.

Abstract

Insights

Fyn kinase is overexpressed in melanoma. A novel inhibitor, Lj-1-60, effectively suppresses melanoma cell growth by targeting Fyn and Stat3, offering a promising therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Fyn kinase exhibits oncogenic properties in various tumors.
  • Its role and specific inhibitors in melanoma remain underexplored, highlighting a therapeutic gap.

Purpose of the Study:

  • To investigate the function of Fyn in melanoma.
  • To identify and characterize novel Fyn inhibitors for melanoma treatment.

Main Methods:

  • Bioinformatics analysis, western blot, cell viability, cell cycle, apoptosis assays, and xenograft models were employed.
  • In vitro kinase assays and pull-down assays confirmed Lj-1-60's direct targeting of Fyn.
  • Transcriptome sequencing and RT-PCR elucidated Lj-1-60's mechanism of action.

Main Results:

  • Fyn is overexpressed in melanoma; its knockdown inhibits proliferation.
  • A novel chalcone derivative, Lj-1-60, was identified as a potent Fyn inhibitor with low toxicity and high anti-tumor efficacy.
  • Lj-1-60 suppressed melanoma growth in vitro and in vivo by inducing cell cycle arrest and apoptosis, abrogating Stat3 activation.

Conclusions:

  • Lj-1-60 directly inhibits Fyn kinase activity, impacting Stat3 signaling.
  • This novel Fyn inhibitor demonstrates significant potential for melanoma treatment.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.7K